Patents Represented by Attorney Susan M. Pellegrino

Find this attorney in the Justia Lawyer Directory

  • Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
    Patent number: 6972319
    Abstract: This invention provides novel peptides that function in vivo to stimulate insulin release from pancreatic beta cells in a glucose-dependent fashion. These insulin secretagogue peptides are shown to stimulate insulin release in rat islet cells in vitro, and in vivo. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, in particular type 2 diabetics. In particular, the invention is a polypeptide selected from a specific group of VIP/PACAP-related polypeptides, or functional equivalents thereof. The invention is also directed to a method of treating a metabolic disease in a mammal comprising administering a therapeutically effective amount of the insulin secretagogue peptides to said mammal. Also disclosed are methods of making the peptides, both recombinant and synthetic.
    Type: Grant
    Filed: September 27, 2000
    Date of Patent: December 6, 2005
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Clark Pan, Manami Tsutsumi, Armen B. Shanafelt
  • 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders
    Patent number: 6964971
    Abstract: The invention relates generally to naphthyridine derivatives of the formula wherein one of U, X, Y and Z is nitrogen and the others are C—R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,6-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.
    Type: Grant
    Filed: October 10, 2003
    Date of Patent: November 15, 2005
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Yamin Wang, William H. Bullock, Libing Chen
  • Preparation and use of imidazole derivatives for treatment of obesity
    Patent number: 6960601
    Abstract: This invention relates to substituted imidazole derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.
    Type: Grant
    Filed: September 24, 2002
    Date of Patent: November 1, 2005
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Roger A. Smith, Stephen J. O'Connor, Stephan-Nicholas Wirtz, Wai C. Wong, Soongyu Choi, Harold C. E. Kluender, Ning Su, Gan Wang, Furahi Achebe, Shihong Ying
  • Cyclopentabenzofuran derivatives and their use
    Patent number: 6943182
    Abstract: The invention relates to cyclopentabenzofuran derivatives, process for their preparation, the use of cyclopentabenzofuran derivatives for the production of a medicament for the therapy of NF-?B-dependent diseases and medicaments which contain the cyclopentabenzofuran derivatives.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: September 13, 2005
    Assignee: Bayer Aktiengesellschaft
    Inventors: Walter Guarnieri, Thomas Jaetsch, Andreas Schoop, Jörg Baumgarten, Axel Kretschmer, Horst-Peter Antonicek
  • 7-Alkyl and cycloalkyl-substituted imidazotriazinones
    Patent number: 6943163
    Abstract: The present invention relates to 7-alkyl- and cycloalkyl-substituted imidazotriazinones, to processes for their preparation and to their use as medicaments, in particular as inhibitors of cGMP-metabolizing phosphodiesterases.
    Type: Grant
    Filed: May 20, 2004
    Date of Patent: September 13, 2005
    Assignee: Bayer Aktiengesellschaft
    Inventors: Ulrich Niewöhner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Gunter Schmidt, Karl-Heinz Schlemmer, Erwin Bischoff, Klaus Dembowsky, Elisabeth Perzborn
  • Imidazotriazines for use as phosphodiesterase inhibitors
    Patent number: 6936609
    Abstract: The invention relates to new imidazotriazines, processes for their preparation, and their use for the production of medicaments for the treatment and/or prophylaxis of neurodegenerative disorders, in particular Parkinson's disease.
    Type: Grant
    Filed: June 10, 2002
    Date of Patent: August 30, 2005
    Assignee: Bayer HealthCare AG
    Inventors: Jens-Kerim Ergüden, Marcus Bauser, Nils Burkhardt, Dietmar Flubacher, Arno Friedl, Irene Gerlach, Volker Hinz, Reinhard Jork, Paul Naab, Maria Theresia Niewöhner, Thorsten Oliver Repp, Karl-Heinz Schlemmer, Jürgen Stoltefuss, David Brückner, Martin Hendrix, Dagmar Schauss, Adrian Tersteegen, Ulrich Niewöhner
  • Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors
    Patent number: 6930114
    Abstract: The present invention relates to pyrrolo[2.1-a]dihydroisoquinolines which are inhibitors of phosphodiesterase 10a and can be used for combating cancer.
    Type: Grant
    Filed: December 4, 2001
    Date of Patent: August 16, 2005
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Maria Theresia Niewöhner, Marcus Bauser, Jens-Kerim Ergüden, Dietmar Flubacher, Paul Naab, Thorsten-Oliver Repp, Jürgen Stoltefuss, Nils Burkhardt, Andrea Sewing, Michael Schauer, Karl-Heinz Schlemmer, Olaf Weber, Stephen J. Boyer, Mark Miglarese, Ulrich Niewöhner
  • Use of 2-alkoxyphenol-substituted imidazotriazinones
    Patent number: 6930108
    Abstract: The present invention relates to the use of known 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position and cGMP PDE-inhibitory properties for the production of medicaments for the treatment of cardiac insufficiency, psoriasis, female infertility, cancer, diabetes, ophthalmic disorders such as glaucoma, disorders of gastric motility, cystic fibrosis, premature labour, pulmonary hypertension, bladder disorders, prostate hyperplasia, nitrate-induced tolerance, pre-eclampsia, alopecia, Parkinson's disease, pain, tinnitus or the renal syndrome.
    Type: Grant
    Filed: July 17, 2002
    Date of Patent: August 16, 2005
    Assignee: Bayer HealthCare AG
    Inventors: Maria Theresia Niewöhner, Erwin Bischoff, Helmut Haning, Afssaneh Rahbar, Tiemo-Joerg Bandel, Wolfgang Barth, Ulrich Niewöhner
  • Benzisothiazolyl-substituted aminomethyl chromanes for treating diseases of the central nervous system
    Patent number: 6919360
    Abstract: The present invention relates to chromans, to processes for their preparation and to their use in medicaments, in particular as agents for treating disorders of the central nervous system.
    Type: Grant
    Filed: September 18, 2002
    Date of Patent: July 19, 2005
    Assignee: Bayer HealthCare AG
    Inventors: Dietrich Scherling, Wolfgang Karl, Dietrich Seidel, Corinna Weinz, Rudolf Schohe-Loop, Frank Mauler
  • 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
    Patent number: 6919371
    Abstract: This invention relates to novel 2,6-substituted chroman derivatives which are useful in the treatment of beta-3 adrenoreceptor-mediated conditions.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: July 19, 2005
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Stephen J. O'Connor, Gaetan H. Ladouceur, William H. Bullock, Ann-Marie Campbell, Miao Dai, Robert Dally, Jacques Dumas, Holia N. Hatoum-Mokdad, Uday Khire, Wendy Lee, Qingjie Liu, Derek B. Lowe, Steven R. Magnuson, Ning Qi, Tatiana E. Shelekhin, Quanrong Shen, Roger A. Smith, Ming Wang
  • Aryl and heteroaryl sulfonates
    Patent number: 6919470
    Abstract: The invention relates to novel aryl and heteroaryl sulfonates of formula (Ia) and to methods for producing them and to novel aryl and heteroaryl sulfonates of formula (I) for treating and/or preventing diseases, especially for treating pain and neurodegenerative diseases, A representing (C6-C10)-aryl or 5-10-membered heteroaryl, D representing (C6-C10)-arylene or 5-10-membered heteroarylene, R1 representing (C4-C8)-alkyl, (C2-C8)-alkyl, the carbon chain being interrupted by one or two heteroatoms or groups chosen from the following group: —O—, —S—, —SO— and —SO2—, (C2-C8)-alkenyl or (C2-C8)-alkinyl, in formula (Ia); and R1 representing (C3-C8)-alkyl, (C2-C8)-alkyl, the carbon chain being interrupted by one or two heteroatoms or groups chosen from the following group: —O—, —S—,—SO— and —SO2—, (C2-C8)-alkenyl or (C2-C8)-alkinyl.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: July 19, 2005
    Assignee: Bayer Aktiengesellschaft
    Inventors: Markus Heil, Heinrich Meier, Paul Naab, Arnd Voerste, Jean-Marie-Viktor de Vry, Dirk Denzer, Frank Mauler, Klemens Lustig, Volker Hinz, Swen Allerheiligen
  • Sulfonamide substituted chroman derivatives
    Patent number: 6903218
    Abstract: This invention related to novel sulfonamide substituted chroman derivatives which are useful in the treatment of beta-3 receptor mediated conditions.
    Type: Grant
    Filed: September 19, 2003
    Date of Patent: June 7, 2005
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Gaetan H. Ladouceur, Richard D. Connell, Jeremy Baryza, Ann-Marie Campbell, Timothy G. Lease, James H. Cook
  • 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders
    Patent number: 6900205
    Abstract: The invention relates generally to naphthyridine derivatives of the formula wherein one of U, X, Y and Z is nitrogen and the others are C—R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,8-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.
    Type: Grant
    Filed: September 23, 2002
    Date of Patent: May 31, 2005
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Yamin Wang, William H. Bullock, David E. Gunn, Qingjie Liu, Sidney X. Liang, Donglei Liu, Steven R. Magnuson, Tindy Li, Eric S. Mull, Jill E. Wood, Ning Qi
  • 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
    Patent number: 6890922
    Abstract: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
    Type: Grant
    Filed: February 12, 2003
    Date of Patent: May 10, 2005
    Assignee: Bayer Healthcare AG
    Inventors: Maria Niewohner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jörg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Serno, Marc Nowakowski, Ulrich Niewöhner
  • Imidazotriazinones and the use thereof
    Patent number: 6878708
    Abstract: Novel imidazotriazinones of general formula (I), a method for the production and the pharmaceutical use thereof are disclosed.
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: April 12, 2005
    Assignee: Bayer Aktiengesellschaft
    Inventors: Maria Niewöhner, Mazen Es-Sayed, Thomas Lampe, Helmut Haning, Gunter Schmidt, Karl-Heinz Schlemmer, Erwin Bischoff, Klaus Dembowsky, Elisabeth Perzborn, Ulrich Niewöhner
  • Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
    Patent number: 6864069
    Abstract: The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders.
    Type: Grant
    Filed: October 3, 2002
    Date of Patent: March 8, 2005
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Clark Pan, James Whelan, Kevin B. Clairmont
  • 7-alkyl-and cycloalkyl-substituted imidazotriazinones
    Patent number: 6838459
    Abstract: The present invention relates to 7-alkyl- and cycloalkyl-substituted imidazotriazinones, to processes for their preparation and to their use as medicaments, in particular as inhibitors of cGMP-metabolizing phosphodiesterases.
    Type: Grant
    Filed: September 20, 2002
    Date of Patent: January 4, 2005
    Assignee: Bayer Aktiengesellschaft
    Inventors: Ulrich Niewöhner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Gunter Schmidt, Karl-Heinz Schlemmer, Erwin Bischoff, Klaus Dembowsky, Elisabeth Perzborn
  • Imidazo[1,3,5]triazinones and the use thereof
    Patent number: 6803365
    Abstract: The invention relates to imidazo[1.3.5]triazinones, a method for their production and methods of use, in particular as inhibitors of cyclic GMP metabolizing phosphodiesterases.
    Type: Grant
    Filed: November 4, 2002
    Date of Patent: October 12, 2004
    Assignee: Bayer Aktlengesellschaft
    Inventors: Ulrich Niewöhner, Helmut Haning, Thomas Lampe, Mazen Es-Sayed, Gunter Schmidt, Erwin Bischoff, Klaus Dembowsky, Elisabeth Perzborn, Karl-Heinz Schlemmer
  • Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
    Patent number: 6797714
    Abstract: This invention is related to novel carboxyl substituted chroman derivatives which are useful in the treatment of beta-3 receptor mediated conditions.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: September 28, 2004
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Richard D. Connell, Timothy G. Lease, Jeremy L. Baryza
  • Indole derivatives
    Patent number: 6794406
    Abstract: The invention relates to new indole derivatives, processes for their preparation, and their use in medicaments.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: September 21, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Helmut Haning, Michael Woltering, Gunter Schmidt, Hilmar Bischoff, Axel Kretschmer, Verena Vöhringer, Christiane Faeste